Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Vivo Capital, LLC

Q4 2023 · 13F-HR

Vivo Capital, LLCholdings as filed

Filed 2024-02-07 · accession 0001213900-24-010646

$1.22B
Reported value
47
Positions
2023-12-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
834203309SLNOSoleno Therapeutics Inc$338.8M27.7%8,418,093CommonSOLE
38406L103Gracell Biotechnologies Inc$95.8M7.85%9,546,485CommonSOLE
925050106VRNAVerona Pharma PLC$84.5M6.92%4,249,918CommonSOLE
413197104HRMYHarmony Biosciences Holdings Inc$84.2M6.89%2,606,247CommonSOLE
00166B105ALXOALX Oncology Holdings Inc$62.8M5.14%4,220,048CommonSOLE
05337M104Avadel Pharmaceuticals PLC$57.8M4.74%4,096,428CommonSOLE
374163103GERNGeron Corp$50.9M4.17%24,143,681CommonSOLE
880881107430Terns Pharmaceuticals Inc$43.2M3.54%6,657,992CommonSOLE
92790C104VRDNViridian Therapeutics Inc$36.6M2.99%1,678,207CommonSOLE
87650L103TARSTarsus Pharmaceuticals Inc$36.1M2.96%1,784,006CommonSOLE
45114M109Icosavax, Inc.$26.9M2.20%1,704,568CommonSOLE
68062P106OLMAOlema Pharmaceuticals Inc$26.3M2.15%1,873,704CommonSOLE
04635X102CATBUSDAstria Therapeutics Inc$19.1M1.56%2,482,727CommonSOLE
02083G100NVLSEURAlpine Immune Sciences Inc$15.6M1.28%819,275CommonSOLE
89157D105TRMLTourmaline Bio Inc.$15.5M1.27%591,882CommonSOLE
20451W101CMPSCompass Pathway PLC$14.1M1.15%1,608,000CommonSOLE
26818M108DYNDyne Therapeutics Inc$13.8M1.13%1,035,136CommonSOLE
19240Q201COGTCogent Biosciences Inc$13.2M1.08%2,244,941CommonSOLE
92337C203VSTMVerastem Inc$12.5M1.03%1,538,461CommonSOLE
22663K107CRNXCrinetics Pharmaceuticals Inc$12.5M1.02%350,000CommonSOLE
449778109IOBTQIO Biotech Inc$11.6M0.95%6,173,439CommonSOLE
98887Q104ZLABZai Lab Ltd$11.3M0.92%411,677CommonSOLE
03770N101APGEApogee Therapeutics Inc$11.2M0.92%400,000CommonSOLE
483497103KALVKalVista Pharmaceuticals Inc.$10.5M0.86%856,008CommonSOLE
37186H209Genetron Holdings Ltd$10.0M0.82%2,708,056CommonSOLE
81749D107SERASera Prognostics Inc$9.9M0.81%1,650,440CommonSOLE
805111101SVRASavara Inc$9.8M0.80%2,088,323CommonSOLE
82686Q101SLNSilence Therapeutics PLC$8.9M0.73%510,204CommonSOLE
01671P100ALLKGUSDAllakos Inc$8.2M0.67%2,988,000CommonSOLE
N69605108PHVSPharvaris NV$8.0M0.65%285,000CommonSOLE
68622P109ORICOric Pharmaceuticals Inc$7.8M0.64%849,681CommonSOLE
75525N107Rayzebio Inc$6.9M0.56%110,581CommonSOLE
29286M105Engene Holdings Inc.$6.3M0.51%678,705CommonSOLE
20454B104CMPXCompass Therapeutics Inc$5.5M0.45%3,556,023CommonSOLE
462260100IOVAIovance Biotherapeutics Inc$5.3M0.44%655,057CommonSOLE
45783C200TILInstil Bio Inc$4.8M0.39%624,340CommonSOLE
04280A100ARWRArrowhead Pharmaceuticals Inc$4.2M0.34%137,411CommonSOLE
097702104BOLT1EURBolt Therapeutics Inc$3.9M0.32%3,521,291CommonSOLE
24661P807DCTHDelcath Systems, Inc.$3.6M0.29%855,191CommonSOLE
76200L309RZLTRezolute Inc$3.2M0.26%3,242,842CommonSOLE
90466Y103Unicycive Therapeutics$3.0M0.25%3,470,152CommonSOLE
23306J101DBV Technologies SA$2.6M0.21%2,708,875CommonSOLE
01626L105Aligos Therapeutics Inc$2.4M0.19%3,547,030CommonSOLE
192005106CDXSCodexis, Inc$1.2M0.10%388,144CommonSOLE
00032Q104WHWKAadi Bioscience Inc$1.0M0.08%509,572CommonSOLE
438083107FIXXEURHomology Medicines, Inc.$225,0010.02%370,068CommonSOLE
74019P108Precision Biosciences Inc$51,1930.00%140,255CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.